Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
复制标题
DOI：
10.1007/112_2020_30
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Hu S
中科院分区：
文献类型：
--
作者：
Anderson JT;Huang KM;Lustberg MB;Sparreboom A;Hu S
溶质载体（SLC）转运蛋白家族的成员负责广泛的内源性化合物和外源性物质的细胞内流。这些蛋白质在胃肠道和消除器官如肝脏和肾脏中高度表达，并且被认为在控制药物吸收和消除方面特别重要。许多相同的转运蛋白也在临床上重要的抗癌药物靶向的多种器官中表达，直接影响细胞对这些药物的敏感性，并间接影响治疗相关的副作用。此外，最近开发了涉及使用转运抑制剂的靶向干预策略，并为与降低毒性相关的组合疗法提供了有希望的主要候选药物。更好地理解转运蛋白介导的靶向和脱靶药物处置之间的复杂相互作用将有助于指导这些新型治疗策略的进一步开发，以防止药物在毒性相关器官中蓄积，并提高目前可用治疗方式的安全性。在这份报告中，我们提供了一个更新，特别强调抗癌药物属于紫杉烷类，铂衍生物，核苷类似物，蒽环类这一迅速崛起的领域。
Members of the solute carrier (SLC) family of transporters are responsible for the cellular influx of a broad range of endogenous compounds and xenobiotics. These proteins are highly expressed in the gastrointestinal tract and eliminating organs such as the liver and kidney, and are considered to be of particular importance in governing drug absorption and elimination. Many of the same transporters are also expressed in a wide variety of organs targeted by clinically important anticancer drugs, directly affect cellular sensitivity to these agents, and indirectly influence treatment-related side effects. Furthermore, targeted intervention strategies involving the use of transport inhibitors have been recently developed, and have provided promising lead candidates for combinatorial therapies associated with decreased toxicity. Gaining a better understanding of the complex interplay between transporter-mediated on-target and off-target drug disposition will help guide the further development of these novel treatment strategies to prevent drug accumulation in toxicity-associated organs, and improve the safety of currently available treatment modalities. In this report, we provide an update on this rapidly emerging field with particular emphasis on anticancer drugs belonging to the classes of taxanes, platinum derivatives, nucleoside analogs, and anthracyclines.
影响因子：
4.1
作者：
Jain L;Gardner ER;Figg WD;Chernick MS;Kong HH
通讯作者：
Kong HH